Table 6. Comparative anti-Leishmania donovani activity of lead compounds in the ex vivo splenic explant model and in vitro infected peritoneal macrophages.
| Ex vivo model | Peritoneal Macrophages | |
| Compound | EC50 (µM; mean±SE) 1 | EC50 (µM; mean±SE) 1 |
| Amphotericin B | 0.09±0.03 | 0.11±0.01 |
| Miltefosine | 1.02±0.08 | 2.28±0.21 |
| Pentamidine | 3.02±0.34 | 0.89±0.37 |
| Fluconazole | >250 | >250 |
| Meglumine antimoniate | 269.60±57.50 | 146.30±42.01 |
| Antimycin A | 1.27±1.07 | 1.67±1.05 |
| Disulfiram | 0.31±0.03 | 0.16±0.03 |
| Monensin A | 0.85±0.68 | 0.23±0.15 |
| Nortriptyline | 6.03±0.28 | 2.65±0.35 |
| Tilorone | 0.84±0.47 | 1.48±0.35 |
1
Effective concentration of the compound that killed 50% of the parasites (EC50). Determined at 48 h of culture by luminometry.